^
    Back
    Association details:
    Biomarker:DICER1 overexpression
    Cancer:Colorectal Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Oncol Pharm Pract
    Title:

    Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer

    Published date:
    08/26/2020
    Excerpt:
    Among colorectal cancer patients, higher DICER1 expression was associated with sensitivity to bevacizumab-based therapy.
    DOI:
    10.1177/1078155220951845